

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 417/12, A61K 31/425		A1	(11) International Publication Number: WO 97/27191
			(43) International Publication Date: 31 July 1997 (31.07.97)
(21) International Application Number: PCT/US97/02577			(72) Inventors: VYAS, Krishnamurthi; Plot No. 12, Jai Prakash Nagar Colony, Miyapur, Hyderabad - 500 050 A.P. (IN). PRABHAKAR, Chebiyyam; H. No. 140/141, Doyens Township, Opposite ALIND, Seri Lingampally, Hyderabad - 500 019 A.P. (IN). RAO, Sreenivas, Dharmaraja; New Krupa Anand Apartments, Block No. 5, Flat No. 18, Anand Bagh Malkajgiri, Hyderabad - 500 047 A.P. (IN). SARMA, Mamillapalli, Ramabadhara; Plot No. 12, Rami Reddy Nagar, Near IDPL Colony, Hyderabad 500 037 A.P. (IN). REDDY, Om, Gaddam; 1-7-23/7A, Jai Santosh Nagar Colony, Street No. 8, Hubsiguda, Hyderabad - 500 007 A.P. (IN). RAMANUJAM, Rajagopalan; 2-B, Vishal Towers, 8-3-682, Navodaya Colony, Yellareddyguda, Hyderabad - 500 873 A.P. (IN). CHAKRABARTI, Ranjan; Ravi Teja Apartments, Flat No. 104, 283/3, RT Sanjeeva Reddy Nagar, Hyderabad - 500 038 A.P. (IN).
(22) International Filing Date: 18 February 1997 (18.02.97)			
(30) Priority Data: 08/665,867 19 June 1996 (19.06.96) US			
(71) Applicants: DR. REDDY'S RESEARCH FOUNDATION [IN/IN]; Bollaram Road, Miyapur, Hyderabad - 500 138 A.P. (IN). REDDY-CHEMINOR, INC. [US/US]; 66 South Maple Avenue, Ridgewood, NJ 07450 (US).			
			(74) Agents: RICHARDS, John; Ladas & Parry, 26 West 61st Street, New York, NY 10023 (US) et al.
			(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
			Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> <i>Before the expiration of the time limit referred to in Article 21(2)(a) on the request of the applicant.</i>
(54) Title: NOVEL POLYMORPHIC FORMS OF TROGLITAZONE HAVING ENHANCED ANTI-DIABETIC ACTIVITY AND A PROCESS FOR THEIR PREPARATION			
(57) Abstract Novel polymorphic forms of Troglitazone and methods for preparing the polymorphic forms of Troglitazone. The polymorphic forms of Troglitazone can be used to treat diabetic ailments.			

FOR THE PURPOSES OF INFORMATION ONLY


Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

NOVEL POLYMORPHIC FORMS OF TROGLITAZONE
HAVING ENHANCED ANTI-DIABETIC ACTIVITY
AND A PROCESS FOR THEIR PREPARATION

BACKGROUND OF THE INVENTION

5 This invention relates to a discovery of the
preparation of novel polymorphic/pseudopolymorphic
forms of Troglitazone and process for the preparation
of various polymorphic/pseudopolymorphic forms of
Troglitazone. Troglitazone is 5-[[4-[3(3,4-dihydro-6-
10 hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)
methoxy] phenyl] methyl] 2,4-thiazolidinedione, having
the Formula I shown below. The polymorphic forms
prepared by the process of the present invention are
more active, as an antidiabetic agent, than the
15 hitherto known Troglitazone.



(I)

Out of the many drugs available for the
treatment of diabetic ailments, the thiazolidinedione
derivatives are very prominent and are considered as

- 2 -

much superior effective-constituents compared to the sulphonyl ureas. Troglitazone, one such thiazolidinedione, which exhibited euglycemic effect, was reported in the year 1983 by Sankyo Co. Ltd., Japan (Japanese Patent No. 60-051189/Australian Patent No. 570067) and created interest in the field, ever since.

Previously, the oral diabetic medicines consisting of sulphonyl urea were believed to be effective in bringing down the sugar level in blood (Hypoglycemic) but they lacked efficiency in preventing/reducing diabetes related complications like cataract, nervous break down, retinopathia etc. (which are usually the chronic ailments accompanied by diabetes). Aldose reductase is the enzyme which reduces aldose present in the humans and animals into corresponding polyols which, in turn, are stored or accumulated in the kidneys, peripheral nerves, eye lens of the diabetic patients and manifest themselves in the above mentioned complications.

With a view to prevent/cure the chronic complications of diabetes, research is being conducted round the world in recent times. Troglitazone hitherto known is being considered today as one of the most effective antidiabetic drugs which has a multipurpose activity not only acting on diabetes itself but also on the reduction of the triglycerides and also on the accompanying complications mentioned above. Indeed, the said Troglitazone is emerging as the first drug candidate of euglycemic class of antidiabetic agents.

The latest trend that has, of late, crept into the pharmaceutical industry is the studies on polymorphism in drugs and the difference in the activity of different polymorphic forms of a given drug. By the term polymorphism we mean to include different physical forms, crystal forms, crystalline/liquid crystalline/non-crystalline (amorphous) forms.

This has especially become very interesting after observing that many antibiotics, antibacterials, tranquilizers etc., exhibit polymorphism and some/one of the polymorphic forms of a given drug exhibit superior bio-availability and consequently show much higher activity compared to other polymorphs. Sertraline, Frentizole, Ranitidine, Sulfathiazole, Indomethacine etc. are some of the important examples of pharmaceuticals which exhibit polymorphism.

10

SUMMARY OF THE INVENTION

Sankyo Co. Ltd, Japan states in its annual report (Annu. Rep. Sankyo. Res. lab., 46, pp. 1-57, 1994) that the relative configurations of the diastereomers have been determined by X-ray crystallographic analysis and that the crystal and molecular structure of Troglitazone is under preparation. The report does not touch upon the possibility/observation that Troglitazone exists in different polymorphic forms. There is no published literature regarding such an observation till date. Polymorphism in drugs is a topic of current interest and is evident from the host of patents being granted. To cite a few, U.S. 5,248,699 discusses about five polymorphic forms of Sertraline hydrochloride while EP 014590 describes four polymorphic forms of Frentizole. EP 490648 and EP 022527 also deal with the subject of polymorphism in drugs. The fact that polymorphism in Troglitazone has not been studied earlier coupled with the current interest in the field of polymorphism in drugs prompted us to take up this investigation. Our observations and results form the subject matter of the present invention.

We have, due to our sustained research directed towards finding out effective antidiabetic drugs, observed that Troglitazone can be prepared in different polymorphic forms possessing anti-diabetic activity. We have, in the course of research, prepared

- 4 -

and studied at least six polymorphic forms of Troglitazone. These polymorphs have been designated, by us, as Forms 1,2,3,4,5 & 6.

Our present invention relates to an
5 observation that Troglitazone exhibits polymorphism, which has not been reported till date. Polymorphic Forms 1,2,3 and 6 are obtained by different modes of recrystallization while the polymorphic Forms 4 and 5
10 are derived from melting/heating any of the polymorphic Forms 1,2,3 and 6. A slow recrystallization of the crude Troglitazone gives the polymorphic Form-1. On the other hand, a fast recrystallization of the same crude Troglitazone gives the polymorphic Form-2. This
15 Form-2 of 99% High Pressure Liquid Chromatography (HPLC) purity upon slow recrystallization gives the polymorphic Form-3. Polymorphic Forms 1,2,3 and 6 when melted, produce a glossy/transparent material which on thorough grinding gives a fine powder. This pale
20 yellow powder does not give any peaks due to X-Ray Diffraction (XRD). This could be amorphous/liquid crystalline in nature. This amorphous/liquid crystalline form is designated as Form-4. Interestingly, the non-crystalline Form-4 on isothermal heating at 130°C. yields the crystalline form,
25 designated as Form 5.

All these polymorphic forms were proved to be identical in solution as evident from Nuclear Magnetic Resonance (NMR), Ultra Violet (UV) & Mass spectral data. On the other hand, solid state techniques like
30 Differential Scanning Calorimetry (DSC), Powder X-Ray Diffractometry (XRD) and Infra Red spectroscopy (IR) revealed the difference among these forms.

DSC of the polymorphic Form-1 and polymorphic Form-3 have one melting endotherm each at
35 -180°C. and -186°C. (Figs. 1 & 2) respectively. Polymorphic Form-2 exhibits an endotherm, in the temperature region 110-120°C. (hereafter referred as

Peak 1) before the melting endotherm in the region 165-190°C. as shown in Fig-3. It was also observed that when the polymorphic Form-2 is heated to 150°C. and cooled, the rerecorded DSC thermogram showed the reduction and absence of the peak 1 as represented by Figs. 4 & 5 respectively, indicating the conversion of the polymorphic Form-2 into another polymorphic form completely/partially. It was confirmed by Thermo Gravimetry (TG) - Mass spectroscopic studies that the Peak 1 present in polymorphic Form-2 is not due to any volatile material as there was no weight loss in TG and no mass was detected by analyzing the evolved gases from TG, using mass spectrometry. However, the possibility of mixture of polymorphs constituting this polymorphic Form-2 can not be ruled out. Interestingly, DSC studies on polymorphic Form-4 exhibited (Fig. 6) a small endotherm at -57°C., an exotherm at -100-130°C. and a melting endotherm at -177°C. The endotherm at --57°C. could be because of phase transition/loss of some volatile material. The exotherm at -100-130°C. is due to crystallization while the endotherm at -177°C. is due to melting. Hence, in principle, if the amorphous/liquid crystalline polymorphic Form-4 when heated at ~130°C., should result in a crystalline form. It is reasonable to expect the amorphous/liquid crystalline polymorphic Form-4 to acquire crystallinity when heated at ~130°C. Indeed, when the polymorphic Form-4 was heated at 130°C., it attained crystallinity and the DSC of this material exhibited only the melting endotherm (Fig. 7) at -177°C., indicating the absence of phase transition and the disappearance of liquid crystalline nature. The new crystalline form thus obtained is designated as polymorphic Form 5. The DSC study also reveals that the polymorphic Form-4 is not only noncrystalline/liquid crystalline but also metastable in nature. The plausible reason for the enhanced activity of the

polymorphic Form-4 may be due to the thermodynamically less stable nature of noncrystalline/liquid crystalline form. The polymorphic Form-6 exhibits a single melting endotherm at $\sim 105^{\circ}\text{C}$. (Fig. 8).

5 The XRD of the crystalline polymorphic Forms 1,2,3,5 & 6 were found to be different from each other (Figs. 9-13) while the polymorphic Form-4 showed no XRD pattern confirming its amorphous/liquid crystalline nature as shown in the (Fig. 14). Fig. 15 gives the
10 powder X-ray diffraction pattern of the Forms 1,2,3,5 and 6 to facilitate easy comparison.

 The Infrared absorption spectra of Forms 1 to 6 in potassium bromide are different from one another which become apparent only after closer examination.
15 The spectra are depicted in Figs. 16-21 respectively. The overlapped IR spectra of all the Forms 1 - 6 (Fig. 22) and the sectional expansions (Figs. 23-26) are also provided. A qualitative comparison of such spectra, (Figs. 22-26) reveals the following differences.

20 a. Forms 2 & 6 exhibit absorption bands of medium intensity at $\sim 3650\text{ cm}^{-1}$ while no absorption is observed for the others (Fig. 23).

 b. Form 1 exhibits a strong absorption with a shoulder at $\sim 3450\text{ cm}^{-1}$ while Forms 3 & 5 absorb
25 without a shoulder. On the other hand Form 2 exhibits a band at $\sim 3550\text{ cm}^{-1}$, while Form 4 has it at $\sim 3500\text{ cm}^{-1}$ (Fig. 23).

 c. Forms 1 & 2 have a weak absorption at $\sim 3300\text{ cm}^{-1}$, Form 3 has a strong band while no
30 absorption for the rest (Fig. 23).

 d. Forms 1 & 3 have a strong absorption at $\sim 2980\text{ cm}^{-1}$ with a shoulder at $\sim 2925\text{ cm}^{-1}$, while Forms 2, 4 and 5 show only a weak peak at $\sim 2980\text{ cm}^{-1}$ with no shoulder. Form 6 shows no absorption in this region
35 (Fig. 23).

 e. All the forms, show absorption $\sim 1750\text{ cm}^{-1}$ and $\sim 1700\text{ cm}^{-1}$. Only Form 5 shows a shoulder in both

these wavenumbers while Form 1 has a shoulder in the latter (Fig. 24).

f. Forms 2 & 6 have a strong peak at -1255 cm^{-1} , while the rest have it at -1240 cm^{-1} (Fig. 25).

5 g. Form 3 has a weak absorption at -700 cm^{-1} while others have no absorption. (Fig. 26).

h. Form 6 exhibits three weak absorption bands while the others have negligible absorption (Fig. 26).

10

BRIEF DESCRIPTION OF THE FIGURES

Fig. 1 is a characteristic differential scanning calorimetric thermogram of Form 1.

Fig. 2 is a characteristic differential scanning calorimetric thermogram of Form 3.

15

Fig. 3 is a characteristic differential scanning calorimetric thermogram of Form 2.

Fig. 4 is a characteristic differential scanning calorimetric thermogram of Form 2 showing the reduction of peak 1 after heating.

20

Fig. 5 is a characteristic differential scanning calorimetric thermogram of Form 2 showing the absence of peak 1 after heating.

Fig. 6 is a characteristic differential scanning calorimetric thermogram of Form 4.

25

Fig. 7 is a characteristic differential scanning calorimetric thermogram of Form 5.

Fig. 8 is a characteristic differential scanning calorimetric thermogram of Form 6.

30 Fig. 9 is a characteristic X-ray powder diffraction pattern of Form 1.

Fig. 10 is a characteristic X-ray powder diffraction pattern of Form 2.

Fig. 11 is a characteristic X-ray powder diffraction pattern of Form 3.

35

Fig. 12 is a characteristic X-ray powder diffraction pattern of Form 5.

Fig. 13 is a characteristic X-ray powder

diffraction pattern of Form 6.

Fig. 14 is a characteristic X-ray powder diffraction pattern of Form 4.

Fig. 15 is the multi-plot of X-ray powder diffraction patterns of Forms 1,2,3,5,6.

Fig. 16 is a characteristic infrared absorption spectrum of Form 1 in potassium bromide). (KBr).

Fig. 17 is a characteristic infrared absorption spectrum of Form 2 in KBr.

Fig. 18 is a characteristic infrared absorption spectrum of Form 3 in KBr.

Fig. 19 is a characteristic infrared absorption spectrum of Form 4 in KBr.

Fig. 20 is a characteristic infrared absorption spectrum of Form 5 in KBr.

Fig. 21 is a characteristic infrared absorption spectrum of Form 6 in KBr.

Fig. 22 is the multi-plot of infrared absorption spectra of Forms 1,2,3,4,5,6 (4000-500 cm^{-1}). Common color code for Figs. 22-26: Black - Form 1; Orange - Form 2; Red - Form 3; Violet - Form 4; Blue - Form 5; Green - Form 6.

Fig. 23 is the multi-plot of infrared absorption spectra of Forms 1,2,3,4,5,6 (3800-2400 cm^{-1}).

Fig. 24 is the multi-plot of infrared absorption spectra of Forms 1,2,3,4,5,6 (1800-1500 cm^{-1}).

Fig. 25 is the multi-plot of infrared absorption spectra of Forms 1,2,3,4,5,6 (1500-1100 cm^{-1}).

Fig. 26 is the multi-plot of infrared absorption spectra of Forms 1,2,3,4,5,6 (1125-500 cm^{-1}).

DETAILED DESCRIPTION OF THE INVENTION

Accordingly, the present invention provides a

process for the preparation of novel polymorphic Form-1 of Troglitazone having the Formula I shown in the drawing accompanying this specification which comprises

(i) synthesizing Troglitazone, in crude form
5 employing known methods,

(ii) subjecting the crude Troglitazone obtained in step (i) to column chromatography to obtain a partially purified Troglitazone having HPLC purity in the range of 60-70%,

10 (iii) dissolving the partially purified Troglitazone obtained in step (ii) in an organic polar and/or medium polar solvent and heating the resulting solution with a non-polar solvent and

(iv) cooling the resulting solution slowly
15 to room temperature at a rate of 0.1 to 1°C./minute over a period in the range of 24-72 h to produce the polymorphic Form-1 of Troglitazone which is characterized by the following data.

DSC: Endotherm at 179.3°C. (onset at
20 169.3°C.) (Fig. 1)

X-ray powder diffraction (2 θ): 5.56, 11.10, 11.66, 15.72, 16.62, 17.62, 18.24, 19.70, 21.20, 21.42, 22.32, 23.40, 23.70, 24.06, 24.36, 26.26. (Fig. 9)

Infrared absorption bands (cm⁻¹): 3442(w),
25 3218(w), 2921(w), 1748(m), 1686(s), 1610(w), 1582(w), 1513(s), 1454(w), 1420(w), 1382(w), 1302(m), 1244(s), 1169(m), 1118(w), 1086(w), 1048(m), 931(w), 863(w), 827(w), 798(w), 720(w), 509(w). (Fig. 16)

w = weak, m = medium, s = strong

30 According to another feature of the invention, there is provided a process for the preparation of novel polymorphic Form-2 of Troglitazone having the Formula I which comprises

(i) synthesizing Troglitazone, in crude form
35 employing known methods,

(ii) subjecting the crude Troglitazone obtained in step (i) to column chromatography to obtain

- 10 -

a partially purified Troglitazone having HPLC purity in the range of 60-70%,

(iii) dissolving the partially purified Troglitazone obtained in step (ii) in an organic polar and/or medium polar solvent and heating the resulting solution with a non-polar solvent, and

(iv) scratching the resulting solution, while cooling rapidly to a temperature between 0 to -20°C. at a rate of 2 to 10°C./minute over a period in the range of 10-30 min. to precipitate the polymorphic Form-2 of Troglitazone which is characterized by the following data.

DSC: Endotherms at 110.1°C. (onset at 102.4°C.) and at 175.1°C. (onset at 155.9°C.) (Fig. 3)

X-ray powder diffraction (2 θ): 5.40, 10.24, 10.70, 11.70, 12.18, 12.44, 12.66, 13.20, 15.60, 16.02, 16.50, 17.58, 18.16, 18.82, 19.62, 20.40, 20.64, 21.44, 22.22, 23.30, 23.68, 24.16, 24.44, 26.54, 27.82, 29.20, 31.48 (Fig. 10)

Infrared absorption bands (cm⁻¹): 3506(w), 3187(w), 3061(w), 2931(w), 1751(m), 1688(s), 1610(w), 1583(w), 1512(s), 1454(w), 1419(w), 1381(w), 1334(w), 1301(m), 1252(s), 1165(m), 1088(w), 1047(w), 932(w), 828(w), 722(w), 511(w) (Fig. 17)

w = weak, m = medium, s = strong

According to yet another embodiment of the present invention, there is provided a process for the preparation of a novel polymorphic Form-3 of Troglitazone, having the Formula I, which comprises

(i) synthesizing Troglitazone, in crude form employing known methods,

(ii) subjecting the crude Troglitazone obtained in step (i) to column chromatography to obtain a partially purified Troglitazone having HPLC purity in the range of 60-70%,

(iii) dissolving the partially purified Troglitazone obtained in step (ii) in an organic polar

- 11 -

and/or medium polar solvent and heating the resulting solution with a non-polar solvent, and

(iv) scratching the resulting solution, while cooling rapidly to a temperature between 0 to
5 -20°C. at a rate of 2 to 10°C./minute over a period in the range of 10-30 min. to precipitate the polymorphic Form-2 of Troglitazone.

(v) dissolving the polymorphic Form-2 of Troglitazone so obtained in step (iv) in an organic
10 polar and/or medium polar solvent and heating the resulting solution with a non-polar solvent, and

(vi) heating the resulting solution on steam bath and cooling the solution slowly to room temperature at a rate of 0.1 to 1°C./minute over a
15 period in the range of 24-72 h to crystallize the polymorphic Form-3 of Troglitazone which is characterized by the following data.

DSC: Endotherm at 185.8°C. (onset at 175.4°C.) (Fig. 2)

20 X-ray powder diffraction (2 θ): 5.45, 11.76, 13.24, 15.63, 16.03, 17.58, 18.13, 19.66, 21.42, 23.37, 23.67, 24.45, 26.53. (Fig. 11)

Infrared absorption bands (cm⁻¹): 3439(w), 3295(w), 2972(w), 2932(w), 1747(m), 1690(s), 1611(w),
25 1582(w), 1512(s), 1453(m), 1384(w), 1302(m), 1245(s), 1221(s), 1169(s), 1143(w), 1119(w), 1089(w), 1049(w), 931(w), 828(w), 722(w), 510(w) (Fig. 18)

w = weak, m = medium, s = strong

According to yet another embodiment of the
30 present invention, there is provided a process for the preparation of a novel polymorphic Form-4 of Troglitazone, having the Formula I, which comprises

(i) synthesizing Troglitazone, in crude form employing known methods,
35 (ii) subjecting the crude Troglitazone obtained in step (i) to column chromatography to obtain a partially purified Troglitazone having HPLC purity in

- 12 -

the range of 60-70%,

(iii) dissolving the partially purified Troglitazone obtained in step (ii) in an organic polar and/or medium polar solvent and heating the resulting solution with a non-polar solvent,

(iv) cooling the resulting solution slowly to room temperature at a rate of 0.1 to 1°C./minute over a period in the range of 24-72 h to produce the polymorphic Form-1 of Troglitazone,

(v) filtering the product and melting it by heating,

(vi) cooling the melt to ambient temperature slowly at a rate of 0.1 to 1°C./minute over a period in the range of 1-4 h to give a glossy transparent material,

(vii) grinding the transparent flake to a fine powder to yield the polymorphic Form-4 of Troglitazone which is characterized by the following data.

DSC: Endotherm at 56.6°C., exotherm at 110.4°C. (onset at 93.6°C.) and endotherm 177.1°C. (onset at 153.7°C.) (Fig. 6)

X-ray powder diffraction (2 θ): No diffraction peaks due to its amorphous nature (Fig. 14)

Infrared absorption bands (cm⁻¹): 3473(w), 3204(w), 3060(w), 2924(w), 1754(m), 1696(s), 1610(w), 1583(w), 1512(s), 1457(m), 1420(w), 1378(w), 1333(m), 1301(m), 1243(s), 1162(m), 1115(w), 1085(w), 1041(w), 928(w), 849(w), 827(w), 715(w), 664(w), 512(w) (Fig. 19)

w = weak, m = medium, s = strong

According to yet another embodiment of the present invention, there is provided a process for the preparation of the novel polymorphic Form-4 of Troglitazone, having the Formula I, which comprises

(i) synthesizing Troglitazone, in crude form employing known methods,

- 13 -

(ii) subjecting the crude Troglitazone obtained in step (i) to column chromatography to obtain a partially purified Troglitazone having HPLC purity in the range of 60-70%,

5 (iii) dissolving the partially purified Troglitazone obtained in step (ii) in an organic polar and/or medium polar solvent and heating the resulting solution with a non-polar solvent,

(iv) scratching while cooling rapidly to a
10 temperature in the range of 0 to -20°C. at a rate of 2 to 10°C./minute, over a period in the range of 10-30 min. to precipitate the polymorphic Form-2 of Troglitazone,

(v) filtering the product and melting it by
15 heating,

(vi) cooling the melt to ambient temperature slowly at a rate of 0.1 to 1°C./minute over a period in the range of 1-4 h to give a glossy transparent material,

20 (vii) grinding the transparent flake to a fine powder to yield the polymorphic Form-4 of Troglitazone which is characterized by the data presented in the previous method.

According to yet another embodiment of the
25 present invention, there is provided a process for the preparation of the novel polymorphic Form-4 of Troglitazone, having the Formula I, which comprises

(i) synthesizing Troglitazone, in crude form employing known methods,

30 (ii) subjecting the crude Troglitazone obtained in step (i) to column chromatography to obtain a partially purified Troglitazone having HPLC purity in the range of 60-70%,

(iii) dissolving the partially purified
35 Troglitazone obtained in step (ii) in an organic polar and/or medium polar solvent and heating the resulting solution with a non-polar solvent,

- 14 -

(iv) scratching the resulting solution, while cooling rapidly to a temperature in the range of 0 to -20°C. at a rate of 2 to 10°C./minute, over a period in the range of 10-30 min. to precipitate the polymorphic Form-2 of Troglitazone,

(v) dissolving the polymorphic Form-2 of Troglitazone so obtained in step (iv), in an organic polar and/or medium polar solvent and heating the resulting solution with a non-polar solvent,

(vi) heating the resulting solution preferably on steam bath and cooling the solution slowly to room temperature at a rate of 0.1 to 1°C./minute, over a period in the range of 24-72 h to crystallize the polymorphic Form-3 of Troglitazone,

(vii) filtering the product and melting it by heating,

(viii) cooling the melt to ambient temperature slowly at a rate of 0.1 to 1°C./minute, over a period in the range of 1-4 h to give a glossy transparent material

(ix) grinding the transparent flake to a fine powder to yield the polymorphic Form-4 of Troglitazone which is characterized by the data presented in the previous method.

According to a further embodiment of the present invention, there is provided a process for the preparation of a novel polymorphic Form-5 of Troglitazone having the Formula I, which comprises

(i) synthesizing Troglitazone, in crude form employing known methods,

(ii) subjecting the crude Troglitazone obtained in step (i) to column chromatography to obtain a partially purified Troglitazone having HPLC purity in the range of 60-70%,

(iii) dissolving the partially purified Troglitazone obtained in step (ii) in an organic polar and/or medium polar solvent and heating the resulting

- 15 -

solution with a non-polar solvent,

(iv) cooling the resulting solution slowly to room temperature at a rate of 0.1 to 1°C./minute, over a period in the range of 24-72 h to produce the polymorphic Form-1 of Troglitazone,

(v) filtering the product and melting it by heating,

(vi) cooling the melt to ambient temperature at a rate of 0.1 to 1°C./minute over a period in the range of 1-4 h to give a glossy transparent material,

(vii) grinding the transparent flake to a fine powder to yield the polymorphic Form-4 of Troglitazone,

(viii) subjecting the polymorphic Form-4 of Troglitazone so obtained in step (vii) to isothermal heating in the range of 60 to 170°C. preferably at 130°C., for a period in the range of 5 min. to 4 h, cooling to ambient temperature slowly at a rate of 0.1 to 1°C./minute, over a period in the range of 1-4 h, followed by grinding the flake to a fine powder to yield the polymorphic Form 5 of Troglitazone which is characterized by the following data.

DSC: Endotherm at 180.5°C. (onset at 157.9°C.) (Fig. 7)

X-ray powder diffraction (2 θ): 5.56, 11.02, 11.58, 15.38, 15.80, 16.42, 18.08, 18.34, 21.06, 21.84, 22.14, 23.32. (Fig. 12)

Infrared absorption bands (cm⁻¹): 3462(w), 3211(w), 3060(w), 2921(w), 1756(m), 1685(s), 1610(w), 1583(w), 1513(s), 1454(m), 1419(w), 1381(w), 1303(m), 1244(s), 1168(m), 1117(w), 1085(w), 1047(m), 929(w), 861(w), 825(w), 718(w), 665(w), 564(w), 509(w) (Fig. 20).

w = weak, m = medium, s = strong

According to a further embodiment of the present invention, there is provided a process for the preparation of a novel polymorphic Form-5 of

- 16 -

Troglitazone having the Formula I, which comprises

(i) synthesizing Troglitazone, in crude form employing known methods,

5 (ii) subjecting the crude Troglitazone obtained in step (i) to column chromatography to obtain a partially purified Troglitazone having HPLC purity in the range of 60-70%,

10 (iii) dissolving the partially purified Troglitazone obtained in step (ii) in an organic polar and/or medium polar solvent and heating the resulting solution with a non-polar solvent,

15 (iv) scratching while cooling rapidly to a temperature in the range of 0 to -20°C. at a rate of 2 to 10°C./minute, over a period in the range of 10-30 min. to precipitate the polymorphic Form-2 of Troglitazone,

(v) filtering the product and melting it by heating,

20 (vi) cooling the melt to ambient temperature slowly at a rate of 0.1 to 1°C./minute, over a period in the range of 1-4 h to give a glossy transparent material,

25 (vii) grinding the transparent flake to a fine powder to yield the polymorphic Form-4 of Troglitazone,

30 (viii) subjecting the polymorphic Form-4 of Troglitazone so obtained in step (vii) to isothermal heating in the range of 60 to 170°C. preferably at 130°C. for a period in the range of 5 min. to 4 h, cooling to ambient temperature at a rate of 0.1 to 1°C./minute, over a period in the range of 1-4 h followed by grinding the flake to a fine powder to yield the polymorphic Form-5 of Troglitazone which is characterized by the data presented in the previous
35 method.

According to a further embodiment of the present invention, there is provided a process for the

- 17 -

preparation of a novel polymorphic Form-5 of Troglitazone having the Formula I, which comprises

(i) synthesizing Troglitazone, in crude form employing known methods,

5 (ii) subjecting the crude Troglitazone obtained in step (i) to column chromatography to obtain a partially purified Troglitazone having HPLC purity in the range of 60-70%,

(iii) dissolving the partially purified
10 Troglitazone obtained in step (ii) in an organic polar and/or medium polar solvent and heating the resulting solution with a non-polar solvent,

(iv) scratching the resulting solution, while cooling rapidly to a temperature in the range of
15 0 to -20°C. at a rate of 2-10°C./minute, over a period in the range of 10-30 min. to precipitate the polymorphic Form-2 of Troglitazone,

(v) dissolving the polymorphic Form-2 of Troglitazone so obtained in step (iv) in an organic
20 polar and/or medium polar solvent and heating the resulting solution with a non-polar solvent,

(vi) heating the resulting solution preferably on a steam bath and cooling the solution slowly to room temperature at a rate of 0.1 to
25 1°C./minute, over a period in the range of 24-72 h to crystallize the polymorphic Form-3 of Troglitazone,

(vii) filtering the product and melting it by heating,

(viii) cooling the melt to ambient
30 temperature at a rate of 0.1 to 1°C./minute, over a period in the range of 1-4 h to give a glossy transparent material,

(ix) grinding the transparent flake to a fine powder to yield the polymorphic Form-4 of
35 Troglitazone,

(x) subjecting the polymorphic Form-4 of Troglitazone obtained in step (ix) to isothermal

- 18 -

heating in the range of 60 to 170°C. preferably at 130°C. for a period in the range of 5 min. to 4 h, cooling to ambient temperature slowly at a rate of 0.1 to 1°C./minute, over a period in the range of 1-4 h followed by grinding the flake to a fine powder to yield the polymorphic Form-5 of Troglitazone which is characterized by the data presented in the previous method.

According to yet another embodiment of the present invention there is provided a process for the preparation of novel polymorphic Form-6 of Troglitazone having the Formula I which comprises

- (i) synthesizing Troglitazone, in crude form employing known methods,
- (ii) subjecting the crude Troglitazone obtained in step (i) to column chromatography to obtain a partially purified Troglitazone having HPLC purity in the range of 60-70%,
- (iii) dissolving the partially purified Troglitazone obtained in step (ii) in an organic polar and/or medium polar solvent and adding a non-polar solvent to the resulting solution and
- (iv) cooling the resulting solution rapidly to -5°C. at a rate of 10°C./minute and maintaining the temperature at -5°C. for a period of 10-16 h to produce the polymorphic Form-6 of Troglitazone which is characterized by the following data.

DSC: Endotherm at 105.4°C. (onset at 94.8°C.) (Fig. 8)

X-ray powder diffraction (2 θ): 8.54, 10.24, 10.70, 11.24, 12.48, 12.68, 14.04, 14.70, 14.74, 15.00, 15.58, 18.52, 18.84, 19.48, 19.74, 20.24, 20.58, 21.38, 21.56, 22.18, 23.20, 23.30, 23.62, 24.10, 25.16, 27.76, 27.86, 28.88, 28.92, 29.12, 31.02 (Fig. 13)

Infrared absorption bands (cm⁻¹): 3634(w), 3514(w), 3176(w), 3060(w), 2930(w), 1753(m), 1686(s), 1610(w), 1512(s), 1459(w), 1418(w), 1380(w), 1335(m),

- 19 -

1300(m), 1253(s), 1164(s), 1106(w), 1087(w), 1058(w),
1048(w), 937(w), 828(m), 723(w), 673(w), 606(w),
568(w), 515(w) (Fig. 21)

w = weak, m = medium, s = strong

5 According to yet another embodiment of the
present invention, there is provided a process for the
preparation of the novel polymorphic Form-4 of
Troglitazone, having the Formula I, which comprises

10 (i) melting the polymorphic Form-5 of
Troglitazone prepared by any one of the processes
described above, by heating.

15 (ii) cooling the melt to ambient temperature
slowly at a rate of 0.1 to 1°C./minute, over a period
in the range of 1-4 h to give a glossy transparent
material,

 (iii) grinding the transparent flake to a
fine powder to yield the polymorphic Form-4 of
Troglitazone which is characterized by the data
presented earlier.

20 According to yet another embodiment of the
present invention, there is provided a process for the
preparation of the novel polymorphic Form-4 of
Troglitazone, having the Formula I, which comprises

25 (i) melting the polymorphic Form-6 of
Troglitazone prepared by the process described above,
by heating.

30 (ii) cooling the melt to ambient temperature
slowly at a rate of 0.1 to 1°C./minute, over a period
in the range of 1-4 h to give a glossy transparent
material,

 (iii) grinding the transparent flake to a
fine powder to yield the polymorphic Form-4 of
Troglitazone which is characterized by the data
presented earlier.

35 According to yet another embodiment of the
present invention, there is provided a process for the
preparation of the novel polymorphic Form-5 of

- 20 -

Troglitazone, having the Formula I, which comprises

(i) melting the polymorphic Form-6 of Troglitazone prepared by the process described above, by heating.

5 (ii) cooling the melt to ambient temperature slowly at a rate of 0.1 to 1°C./minute, over a period in the range of 1-4 h to give a glossy transparent material.

10 (iii) grinding the transparent flake to a fine powder to yield the polymorphic Form-4 of Troglitazone.

(iv) subjecting the polymorphic Form-4 of Troglitazone obtained in step (iii) to isothermal heating in the range of 60 to 170°C. preferably at 15 130°C. for a period in the range of 5 min. to 4 h, cooling to ambient temperature slowly at a rate of 0.1 to 1°C./minute, over a period in the range of 1-4 h followed by grinding the flake to a fine powder to yield the polymorphic Form-5 of Troglitazone which is 20 characterized by the data presented in the previous method.

The organic polar and/or medium polar solvents are selected from acetonitrile, ethanol, methanol, acetone, 1,4-dioxane, methyl ethyl ketone, 25 ethylacetate, chloroform, tetrahydrofuran, n-propanol, isopropanol, 1,2-dichloroethane, dichloromethane, diethylether, benzene, etc. while the non-polar solvents are selected from hexane, heptane, cyclohexane, carbontetrachloride, toluene, xylene, etc.

30 The present invention is described in detail with examples given below that are provided by way of illustration only and therefore should not be construed to limit the scope of the invention.

35 Process for the preparation of crude Troglitazone of ~70% HPLC purity, the starting material for the preparation of novel polymorphic forms according to the present invention

Example-1:

A mixture of 70 g of ethyl-3-[4-(6-acetoxy-2,5,7,8-tetramethylchroman-2-yl-methoxy)phenyl]-2-chloropropionate, 13.12 g of thiourea and 80.2 ml of sulpholane was reacted for 80 min., under a nitrogen stream at 115-120°C. Subsequently, a 656.2 ml Acetic acid, 218.7 ml conc. hydrochloric acid and 109.4 ml water was added to this and the resulting mixture was further heated for 12 hrs at 85-90°C. The reaction mixture was cooled to room temperature and 196.8 g of sodium bicarbonate was added and once the evolution of carbondioxide had ceased, the solvent was distilled off applying high vacuum. A 10:1 by volume mixture of benzene and ethyl acetate was added to the residue and the crude product was washed with a mixture of equal volumes of a saturated aq. sodium bicarbonate solution & water. The organic layer was dried over anhydrous sodium sulphate and the solvent was distilled off. The resulting crude product was quickly eluted from a silica gel column with 50% ethylacetate-hexane to furnish 40 g of the required 5-[(4-(6-hydroxy-2, 5, 7, 8-tetramethylchroman-2-yl-methoxy) benzyl) thiazolidine-2,4-dione (Troglitazone) with a HPLC purity of ~67-70%. The elution of column was continued further to yield 5-[4-(6-hydroxy-2,5,7,8-tetramethylchroman-2-yl-methoxy)benzyl]2-iminothiazolidine-4-one with HPLC purity of ~70%.

Examples 2-4 illustrate the process for the preparation of the polymorphic Form-1 of Troglitazone

Example-2:

55 g of the crude Troglitazone obtained by the process as described in Example-1 was adsorbed on 60-120 mesh silica gel and extracted first with hexane using a soxhlet and then with benzene. Hexane extract mostly contained the less polar impurities while the benzene extract contained the required product. The benzene extract was concentrated and dried so as to

- 22 -

remove traces of benzene. The gummy material was taken up in dichloromethane and stirred vigorously to obtain a clear solution. The solution was allowed to stand at room temperature for a period of 48 hrs to yield 40 g of > 99% pure polymorphic Form-I of Troglitazone.

Example-3:

15.5 g of 5-[4(6-hydroxy-2,5,7,8-tetramethyl chroman-2-yl-methoxy) benzyl]-2-iminothiazolidine-4-one, prepared by the process as described in Example-1, was added to a mixture of 225 ml of acetic acid, 75 ml of conc. hydrochloric acid and 40 ml of water and the mixture was refluxed for 12 hrs. The reaction mixture was cooled to room temperature and 66.2 g of sodium bicarbonate was added and once the evolution of carbondioxide had ceased, the solvent was distilled off applying high vacuum. A 10:1 by volume mixture of benzene and ethyl acetate was added to the residue and the crude product was washed with a mixture of equal volumes of a saturated aq. sodium bicarbonate solution & water. The organic layer was dried over anhydrous sodium sulphate and the solvent was distilled off. The resulting crude product was quickly eluted from a silica gel column with 50% ethylacetate-hexane to finish 12.5 g of the required 5-{4-(6-hydro-2, 5, 7, 8-tetramethylchroman-2yl-methoxy) benzyl) thiazolidine-2,4-dione (Troglitazone) with a HPLC purity of ~67-70%.

5 g of crude Troglitazone so obtained was taken in ~ 1ml of acetone and ~100 ml benzene was added and heated on a steam bath till the solid dissolved completely. The clear solution was filtered and allowed to cool to room temperature at a rate of 0.1 to 1°C./minute over a period of 48 h to yield 2.5 g of > 99% pure polymorphic Form-1 of Troglitazone.

Example-4:

5 g of crude Troglitazone obtained by the process as described in Example-1 was taken in ~100 ml benzene and heated on steam bath till the solid

completely dissolved and the clear solution was allowed to cool to room temperature at a rate of 0.1 to 1°C./minute during a period ~ 36 h to give 2.5 g of > 99% pure polymorphic Form-1 of Troglitazone.

5 **Examples 5-8 illustrate the process for the preparation of the polymorphic Form-2 of Troglitazone**
Example-5:

55 g of the crude Troglitazone obtained by the process as described in Example-1 was adsorbed on
10 60-120 mesh silica gel and extracted first with hexane using a soxhlet and then with benzene. Hexane extract mostly contained the less polar impurities while the benzene extract contained the required product. The benzene extract was concentrated and dried so as to
15 remove traces of benzene. The gummy material was taken up in dichloromethane and stirred vigorously to obtain a clear solution. The solution was rapidly cooled to -10°C., at a rate of 10°C./minute, over a period of 15 min. while scratching to yield 40 g of > 99% pure
20 polymorphic Form-2 of Troglitazone.

Example-6:

15.5 g of 5[4-(6-hydroxy-2,5,7,8-tetramethyl chroman-2-yl-methoxy) benzyl]-2-iminothiazolidine-4-one, prepared by the process as described in Example-1,
25 was added to a mixture of 225 ml of acetic acid, 75 ml of conc. hydrochloric acid and 40 ml of water and the mixture was refluxed for 12 hrs. The reaction mixture was cooled to room temperature and 66.2 g of sodium bicarbonate was added and once the evolution of
30 carbondioxide had ceased, the solvent was distilled off applying high vacuum. A 10:1 by volume mixture of benzene and ethyl acetate was added to the residue and the crude product was washed with a mixture of equal volumes of a saturated aq. sodium bicarbonate solution
35 & water. The organic layer was dried over anhydrous sodium sulphate and the solvent was distilled off. The resulting crude product was quickly eluted from a

- 24 -

silica gel column with 50% ethylacetate-hexane to furnish 12.5 g of the required 5-{4-(6-hydroxy-2, 5, 7, 8-tetramethylchroma-2yl-methoxy) benzyl} thiazolidine-2,4-dione (Troglitazone) with a HPLC purity of ~67-70%.

5 5 g of crude Troglitazone so obtained was taken in ~1ml of acetone and ~100 ml benzene was added and heated on a steam bath till the solid dissolved completely. The solution was rapidly cooled to -10°C., at a rate of 10°C./minute, over a period of 15 min. while scratching to yield 2.5 g of > 99% pure polymorphic Form-2 of Troglitazone.

Example-7:

15 5 g of crude Troglitazone obtained by the process as described in Example-1 was taken in ~100 ml benzene and heated on steam bath till the solid completely dissolved. The solution was rapidly cooled to -10°C., at a rate of 10°C./minute, over a period of 15 min. while scratching to yield 40 g of > 99% pure polymorphic Form-2 of Troglitazone.

20 Example-8:

25 5 g of crude Troglitazone obtained by the process as described in Example-1 and 5 ml acetone were taken in 100 ml round bottom flask and stirred on a magnetic stirrer till all the solid dissolved in acetone. Acetone was completely removed under vacuum at 50°C., and then ~25 ml dichloromethane was added to the gummy residue and stirred at 5°C. for ½-1 hr. ~50 ml. of Pet ether was added and scratched the walls of the container. Stirring at 5°C. was continued for another 1 hr. The solid was filtered and dried to yield 2.7 g > 99% pure polymorphic Form-2 of Troglitazone.

30 Example 9 illustrates the process for the preparation of the polymorphic Form-3 of Troglitazone

35 Example-9:

10 g of the polymorphic Form-2 of

- 25 -

Troglitazone obtained by the process as described in Example-8, was dissolved in 25 ml acetone and the solvent was completely removed. ~50 ml benzene was added to the gummy mass and heated on a steam bath for 15-30 min. The clear solution was cooled to 5°C. at a rate of 1°C./minute during a period of 24 h to yield 5 g of > 99% pure polymorphic Form-3 of Troglitazone.

Examples 10-14 illustrate the process for the preparation of the polymorphic Form-4 of Troglitazone

10

Example-10:

5 g the polymorphic Form-1 of Troglitazone obtained by the process described in Example-2, was heated to melt and the resulting transparent flake was crushed to give a yellowish white fine powder of the polymorphic Form-4 of Troglitazone in near quantitative yield. This material exhibited typical liquid crystalline/amorphous nature.

15

EXAMPLE-11:

20 5 g of the polymorphic Form-2 of Troglitazone obtained by the process described in Example-5, was heated to melt and the resulting transparent flake was crushed to yield a yellowish white powder of the polymorphic Form-4 of Troglitazone in near quantitative yield which was found to be similar in all respects to the product obtained in Example-10.

25

Example-12:

30 5 g of the polymorphic Form-3 of Troglitazone obtained by the process described in Example-9, was heated to melt and the resulting transparent flake was crushed to yield a yellowish white powder of the polymorphic Form-4 of Troglitazone in near quantitative yield which was found to be similar in all respects to the product obtained in Example-10 and 11.

35

Example-13:

5 g of the polymorphic Form-5 of Troglitazone was heated to melt and the resulting transparent flake

- 26 -

was crushed to yield a yellowish white powder of the polymorphic Form-4 of Troglitazone in near quantitative yield which was found to be similar in all respects to the product obtained in Examples 10-12.

5 **EXAMPLE-14:**

5 g of the polymorphic Form-6 of Troglitazone was heated to melt and the resulting transparent flake was crushed to yield a yellowish white powder of the polymorphic Form-4 of Troglitazone in near quantitative yield which was found to be similar in all respects to the product obtained in Examples 10-13.

Examples 15-19 illustrate the process for the preparation of the polymorphic Form-5 of Troglitazone

15 **EXAMPLE-15:**

5 g of the polymorphic Form-1 of Troglitazone obtained by the process described in Example-1, was heated to melt and the resulting transparent flake was crushed to give a yellowish white fine powder of the polymorphic Form-4 of Troglitazone in near quantitative yield. The polymorphic Form-4 of Troglitazone thus obtained was heated isothermally at a temperature in the range of 60 to 170°C. preferably 130°C. for a period in the range of 5 min. to 4 h, cooled to room temperature at a rate of 0.1 to 1°C./minute and crushed the resulting material to give the polymorphic Form-5 of Troglitazone in near quantitative yield.

EXAMPLE 16:

5 g of the polymorphic Form-2 of Troglitazone, obtained by the process described in Example-5, was heated to melt and the resulting transparent flake was crushed to give a yellowish white fine powder of the polymorphic Form-4 of Troglitazone in near quantitative yield. The polymorphic Form-4 of Troglitazone thus obtained was heated isothermally at a temperature in the range of 60 to 170°C. preferably 130°C. for a period in the range of 5 min. to 4 h,

cooled to room temperature at a rate of 0.1 to 1°C./minute and crushed the resulting material to give the polymorphic Form-5 of Troglitazone in near quantitative yield.

5 EXAMPLE-17:

5 g of the polymorphic Form-3 of Troglitazone obtained by the process described in Example-9, was heated to melt and the resulting transparent flake was crushed to give a yellowish white fine powder of the
10 polymorphic Form-4 of Troglitazone in near quantitative yield. The polymorphic Form-4 of Troglitazone thus obtained was heated isothermally at a temperature in the range of 60 to 170°C. preferably 130°C. for a period in the range of 5 min. to 4 h, cooled to room
15 temperature at a rate of 0.1 to 1°C./minute and crushed the resulting material to give the polymorphic Form-5 of Troglitazone in near quantitative yield.

Example-18:

5 g of the polymorphic Form-4 of Troglitazone
20 obtained by the process described in Example-11, was heated isothermally at a temperature in the range of 60 to 170°C. preferably 130°C. for a period in the range of 5 min. to 4 h, cooled to room temperature at a rate of 0.1 to 1°C./minute and crushed the resulting
25 material to give the polymorphic Form-5 of Troglitazone in near quantitative yield.

Example-19:

5 g of the polymorphic Form-6 of Troglitazone, was heated to melt and the resulting
30 transparent flake was crushed to give a yellowish white fine powder of the polymorphic Form-4 of Troglitazone in near quantitative yield. The polymorphic Form-4 of Troglitazone thus obtained was heated isothermally at a temperature in the range of 60 to 170°C. preferably
35 130°C. for a period in the range of 5 min. to 4 h, cooled to room temperature at a rate of 0.1 to 1°C./minute and crushed the resulting material to give

- 28 -

the polymorphic Form-5 of Troglitazone in near quantitative yield.

Examples 20-21 illustrate the process for the preparation of the

5 polymorphic Form-6 of Troglitazone

Example-20:

5 g of crude Troglitazone obtained by the process as described in Example-1 was dissolved in 25 ml of acetone and to this was added 100 ml of benzene. 10 The clear solution thus obtained was rapidly cooled to 5°C. at the rate of 10°C./minute and allowed to stand at 5°C. for 12 h to yield 2.5 g of > 99.0% pure polymorphic Form-6 of Troglitazone.

Example-21:

15 15.5g of 5[4-(6-hydroxy-2,5,7,8-tetramethyl chroman-2-yl-methoxy) benzyl]-2-iminothiasolidine-4-one, prepared by the process as described in Example-1, was added to a mixture of 225 ml of acetic acid, 75 ml of conc. hydrochloric acid and 40 ml of water and the 20 mixture was refluxed for 12 hrs. The reaction mixture was cooled to room temperature and 66.2 g of sodium bicarbonate was added and once the evolution of carbondioxide had ceased, the solvent was distilled off applying high vacuum. A 10:1 by volume mixture of 25 benzene and ethyl acetate was added to the residue and the crude product was washed with a mixture of equal volumes of a saturated aq. sodium bicarbonate solution & water. The organic layer was dried over anhydrous sodium sulphate and the solvent was distilled off. 30 The resulting crude product was quickly eluted from a silica gel column with 50% ethylacetate-hexane to finish 12.5 g of the required 5-{4-(6-hydroxy-2, 5, 7, 8-tetramethylchroman-2-yl-methoxy) benzyl} thiazolidine-2,4-dione (Troglitazone) with a HPLC 35 purity of- 67-70%.

5 g of crude Troglitazone as obtained above was dissolved in 25 ml of acetone and to this was added

- 29 -

100 ml of benzene. The clear solution thus obtained was rapidly cooled to 5°C. at the rate of 10°C./minute and allowed to stand at 5°C. for 12 h to yield 2.5 g of > 99.0% pure polymorphic Form-6 of Troglitazone.

5

ADVANTAGES OF THE INVENTION

The polymorphic forms of Troglitazone are more active/bio-available.


Ease in formulation resulting in higher activity/bio-availability, in terms of lowering plasma blood sugar and plasma triglycerides.

10

- 30 -

C L A I M S

1. A polymorphic form 1 of Troglitazone having the formula 1,



characterized by the data:


5 DSC: Endotherm at 179.3°C. (onset at 169.3°C.);

X-ray powder diffraction (2θ): 5.56, 11.10, 11.66, 15.72, 16.62, 17.62, 18.24, 19.70, 21.20, 21.42, 23.40, 23.70; and

10 Infrared absorption bands (cm⁻¹): 3442(w), 3218(w), 2921(w), 1748(m), 1686(s), 1610(w), 1582(w), 1513(s), 1454(w), 1420(w), 1382(w), 1302(m), 1244(s), 1169(m), 1118(w), 1086(w), 1048(m), 931(w), 863(w), 827(w), 798(w), 720(w), 509(w) wherein

15 w = weak, m = medium, and s = strong

2. A polymorphic form 2 of Troglitazone having the formula I,



characterized by the data:

20 DSC: Endotherms at 110.1°C. (onset at 102.4°C.) and at a 175.1°C. (onset at 155.9°C.);


X-ray powder diffraction (2θ): 5.42, 10.24, 10.72, 11.58, 11.72, 15.60, 17.56, 18.16, 19.48, 19.58, 19.68, 21.44, 22.20, 23.28, 23.66, 24.14, 24.38; and

- 31 -

Infrared absorption bands (cm^{-1}): 3506(w), 3187(w), 3061(w), 2931(w), 1751(m), 1688(s), 1610(w), 1583(w), 1512(s), 1454(w), 1419(w), 1381(w), 1334(w), 1301(m), 1252(s), 1165(m), 1088(w), 1047(w), 932(w), 828(w), 722(w), 511(w) wherein

w = weak, m = medium, and s = strong

3. A polymorphic form 3 of Troglitazone having the formula 1;



characterized by the data:


10 DSC: Endotherm at 185.8°C. (onset at 175.4°C.);

X-ray powder diffraction (2 θ): 5.44, 11.74, 13.24, 15.62, 16.02, 17.56, 18.12, 19.65, 21.41, 23.00, 23.31, 23.65, 24.43, 26.51; and

15 Infrared absorption bands (cm^{-1}): 3439(w), 3295(w), 2972(w), 2932(w), 1747(m), 1690(s), 1611(w), 1582(w), 1512(s), 1453(m), 1384(w), 1302(m), 1245(s), 1221(s), 1169(s), 1143(w), 1119(w), 1089(w), 1049(w), 931(w), 828(w), 722(w), 510(w) wherein

20 w = weak, m = medium, and s = strong

4. A polymorphic form 4 of Troglitazone having the formula I,



- 32 -


characterized by the data:

DSC: Endotherm at 56.6°C., exotherm at 110.4°C. (onset at 93.6°C.) and endotherm 177.1°C. (onset at 153.7°C.);

5 X-ray powder diffraction (2θ): No diffraction peaks due to its amorphous nature; and

Infrared absorption bands (cm⁻¹): 3473(w), 3204(w), 3060(w), 2924(w), 1754(m), 1696(s), 1610(w), 1583(w), 1512(s), 1457(m), 1420(w), 1378(w), 1333(m), 10
1301(m), 1243(s), 1162(m), 1115(w), 1085(w), 1041(w), 928(w), 849(w), 827(w), 715(w), 664(w), 512(w) wherein
w = weak, m = medium, and s = strong

5. A polymorphic form 5 of Troglitazone having the formula I,




15 characterized by the data:

DSC: Endotherm at 180.5°C. (onset at 157.9°C.);

X-ray powder diffraction (2θ): 5.60, 11.06, 11.62, 15.48, 15.78, 16.48, 18.12, 18.34, 21.06, 21.90, 20 23.34, 23.58; and

Infrared absorption bands (cm⁻¹): 3462(w), 3211(w), 3060(w), 2921(w), 1756(m), 1685(s), 1610(w), 1583(w), 1513(s), 1454(m), 1419(w), 1381(w), 1303(m), 1244(s), 1168(m), 1117(w), 1085(w), 1047(m), 929(w), 25 861(w), 825(w), 718(w), 665(w), 564(w), 509(w) wherein
w = weak, m = medium, and s = strong

6. A polymorphic form 6 of Troglitazone having the formula I,



characterized by the data:


DSC: Endotherm at 105.4°C. (onset at 94.8°C.);

X-ray powder diffraction (2 θ): 5.36, 8.54, 10.24, 10.70, 11.24, 12.48, 12.68, 15.58, 18.84, 19.48, 19.74, 20.58, 21.38, 21.56, 22.18; and

Infrared absorption bands (cm⁻¹): 3634(w), 3514(w), 3176(w), 3060(w), 2930(w), 1753(m), 1686(s), 1610(w), 1512(s), 1459(w), 1418(w), 1380(w), 1335(m), 1300(m), 1253(s), 1164(s), 1106(w), 1087(w), 1058(w), 1048(w), 937(w), 828(m), 723(w), 673(w), 606(w), 568(w), 515(w) wherein

w = weak, m = medium, and s = strong

7. A pharmaceutical composition comprising a polymorphic form 1 of Troglitazone having the formula I,



characterized by the data:

DSC: Endotherm at 179.3°C. (onset at 169.3°C.);


X-ray powder diffraction (2 θ): 5.56, 11.10, 11.66, 15.72, 16.62, 17.62, 18.24, 19.70, 21.20, 21.42, 23.40, 23.70; and

- 34 -

Infrared absorption bands (cm^{-1}): 3442(w), 3218(w), 2921(w), 1748(m), 1686(s), 1610(w), 1582(w), 1513(s), 1454(w), 1420(w), 1382(w), 1302(m), 1244(s), 1169(m), 1118(w), 1086(w), 1048(m), 931(w), 863(w), 827(w), 798(w), 720(w), 509(w) wherein

w = weak, m = medium, and s = strong and a pharmaceutically acceptable carrier diluent or solvent.

8. A pharmaceutical composition comprising a polymorphic form 2 of Troglitazone having the formula I,



characterized by the data:


DSC: Endotherms at 110.1°C. (onset at 102.4°C.) and at 175.1°C. (onset at 155.9°C.);

X-ray powder diffraction (2 θ): 5.42, 10.24, 10.72, 11.58, 11.72, 15.60, 17.56, 18.16, 19.48, 19.58, 19.68, 21.44, 22.20, 23.28, 23.66, 24.14, 24.38; and

Infrared absorption bands (cm^{-1}): 3506(w), 3187(w), 3061(w), 2931(w), 1751(m), 1688(s), 1610(w), 1583(w), 1512(s), 1454(w), 1419(w), 1381(w), 1334(w), 1301(m), 1252(s), 1165(m), 1088(w), 1047(w), 932(w), 828(w), 722(w), 511(w) wherein

w = weak, m = medium, and s = strong and a pharmaceutically acceptable carrier, diluent or solvent.

9. A pharmaceutical composition comprising a polymorphic form 3 of Troglitazone having the formula I,



characterized by the data:


DSC: Endotherm at 185.8°C. (onset at 175.4°C.);

X-ray powder diffraction (2θ): 5.44, 11.74, 13.24, 15.62, 16.02, 17.56, 18.12, 19.65, 21.41, 23.00, 23.31, 23.65, 24.43, 26.51; and

Infrared absorption bands (cm⁻¹): 3439(w), 3295(w), 2972(w), 2932(w), 1747(m), 1690(s), 1611(w), 1582(w), 1512(s), 1453(m), 1384(w), 1302(m), 1245(s), 1221(s), 1169(s), 1143(w), 1119(w), 1089(w), 1049(w), 931(w), 828(w), 722(w), 510(w) wherein

w = weak, m = medium, and s = strong and a pharmaceutically acceptable carrier, diluent or solvent.

10. A pharmaceutical composition comprising a polymorphic form 4 of Troglitazone having the formula I,



characterized by the data:

DSC: Endotherm at 56.6°C., exotherm at 110.4°C. (onset at 93.6°C.) and endotherm 177.1°C. (onset at 153.7°C.);


X-ray powder diffraction (2θ): No diffraction peaks due to its amorphous nature; and

- 36 -

Infrared absorption bands (cm^{-1}): 3473(w), 3204(w), 3060(w), 2924(w), 1754(m), 1696(s), 1610(w), 1583(w), 1512(s), 1457(m), 1420(w), 1378(w), 1333(m), 1301(m), 1243(s), 1162(m), 1115(w), 1085(w), 1041(w), 928(w), 849(w), 827(w), 715(w), 664(w), 512(w) wherein

w = weak, m = medium, and s = strong and a pharmaceutically acceptable carrier, diluent or solvent.

11. A pharmaceutical composition comprising a polymorphic form 5 of Troglitazone having the formula I,



characterized by the data:


DSC: Endotherm at 180.5°C. (onset at 157.9°C.);

15 X-ray powder diffraction (2 θ): 5.60, 11.06, 11.62, 15.48, 15.78, 16.48, 18.12, 18.34, 21.06, 21.90, 23.34, 23.58; and

Infrared absorption bands (cm^{-1}): 3462(w), 3211(w), 3060(w), 2921(w), 1756(m), 1685(s), 1610(w), 1583, 1513(s), 1454(m), 1419(w), 1381(w), 1303(m), 1244(s), 1168(m), 1117(w), 1085(w), 1047(m), 929(w), 861(w), 825(w), 718(w), 665(w), 564(w), 509(w) wherein

20 w = weak, m = medium, and s = strong and a pharmaceutically acceptable carrier, diluent or solvent.

12. A pharmaceutical composition comprising a polymorphic form 6 of Troglitazone having the formula I,



characterized by the data:


DSC: Endotherm at 105.4°C. (onset at 94.8°C.);

X-ray powder diffraction (2θ): 5.36, 8.54, 10.24, 10.70, 11.24, 12.48, 12.68, 15.58, 18.84, 19.48, 19.74, 20.58, 21.38, 21.56, 22.18; and

Infrared absorption bands (cm⁻¹): 3634(w), 3514(w), 3176(w), 3060(w), 2930(w), 1753(m), 1686(s), 1610(w), 1512(s), 1459(w), 1418(w), 1380(w), 1335(m), 1300(m), 1253(s), 1164(s), 1106(w), 1087(w), 1058(w), 1048(w), 937(w), 828(m), 723(w), 673(w), 606(w), 568(w), 515(w) wherein

w = weak, m = medium, and s = strong and a pharmaceutically acceptable carrier, diluent or solvent.

13. A medicine for testing diabetic ailments, the medicine comprising a polymorphic form 1 of Troglitazone having the formula I,



characterized by the data:

DSC: Endotherm at 179.3°C. (onset at 169.3°C.);


X-ray powder diffraction (2θ): 5.56, 11.10, 11.66, 15.72, 16.62, 17.62, 18.24, 19.70, 21.20, 21.42,

23.40, 23.70; and

Infrared absorption bands (cm^{-1}): 3442(w), 3218(w), 2921(w), 1748(m), 1686(s), 1610(w), 1582(w), 1513(s), 1454(w), 1420(w), 1382(w), 1302(m), 1244(s), 1169(m), 1118(w), 1086(w), 1048(m), 931(w), 863(w), 827(w), 798(w), 720(w), 509(w) wherein

w = weak, m = medium, and s = strong and a pharmaceutically acceptable carrier, diluent or solvent.

10 14. A medicine for treating diabetic ailments, the medicine comprising a polymorphic form 2 of Troglitazone having the formula I,



characterized by the data:


DSC: Endotherms at 110.1°C. (onset at 102.4°C.) and at 175.1°C. (onset at 155.9°C.);

X-ray powder diffraction (2 θ): 5.42, 10.24, 10.72, 11.58, 11.72, 15.60, 17.56, 18.16, 19.48, 19.58, 19.68, 21.44, 22.20, 23.28, 23.66, 24.14, 24.38; and

Infrared absorption bands (cm^{-1}): 3106(w), 3187(w), 3061(w), 2931(w), 1751(m), 1688(s), 1610(w), 1583(w), 1512(s), 1454(w), 1419(w), 1381(w), 1334(w), 1301(m), 1252(s), 1165(m), 1088(w), 1047(w), 932(w), 828(w), 722(w), 511(w) wherein

w = weak, m = medium, and s = strong and a pharmaceutically acceptable carrier, diluent or solvent.

15. A medicine for treating diabetic ailments, the medicine comprising a polymorphic form 3 of Troglitazone having the formula I,



characterized by the data:


DSC: Endotherm at 185.8°C. (onset at 175.4°C.);

X-ray powder diffraction (2θ): 5.44, 11.74,
 5 13.24, 15.62, 16.02, 17.56, 18.12, 19.65, 21.41, 23.00,
 23.31, 23.65, 24.43, 26.51; and

Infrared absorption bands (cm⁻¹): 3439(w),
 3295(w), 2972(w), 2932(w), 1747(m), 1690(s), 1611(w),
 1582(w), 1512(s), 1453(m), 1384(w), 1302(m), 1245(s),
 10 1221(s), 1169(s), 1143(w), 1119(w), 1089(w), 1049(w),
 931(w), 828(w), 722(w), 510(w) wherein

w = weak, m = medium, and s = strong and a
 pharmaceutically acceptable carrier, diluent or
 solvent.

15 16. A medicine for treating diabetic ailments,
 the medicine comprising a polymorphic form 4 of
 Troglitazone having the formula I,



characterized by the data:

DSC: Endotherm at 56.6°C., exotherm at
 20 110.4°C. (onset at 93.6°C.) and endotherm 177.1°C.
 (onset at 153.7°C.);


X-ray powder diffraction (2θ): No diffraction
 peaks due to its amorphous nature; and

- 40 -

Infrared absorption bands (cm^{-1}): 3473(w), 3204(w), 3060(w), 2924(w), 1754(m), 1696(s), 1610(w), 1583(w), 1512(s), 1457(m), 1420(w), 1378(w), 1333(m), 1301(m), 1243(s), 1162(m), 1115(w), 1085(w), 1041(w), 928(w), 849(w), 827(w), 715(w), 664(w), 512(w) wherein

w = weak, m = medium, and s = strong and a pharmaceutically acceptable carrier, diluent or solvent.

17. A medicine for treating diabetic ailments, the medicine comprising a polymorphic form 5 of Troglitazone having the formula I,



characterized by the data:


DSC: Endotherm at 180.5°C.) (onset at 157.9°C.);

15 X-ray powder diffraction (2θ): 5.60, 11.06, 11.62, 15.48, 15.78, 16.48, 18.12, 18.34, 21.06, 21.90, 23.34, 23.58; and

Infrared absorption bands (cm^{-1}): 3462(w), 3211(w), 3060(w), 2921(w), 1756(m), 1685(s), 1610(w), 1583(w), 1513(s), 1454(m), 1419(w), 1381(w), 1303(m), 1244(s), 1168(m), 1117(w), 1085(w), 1047(m), 929(w), 861(w), 825(w), 718(w), 665(w), 564(w), 509(w) wherein

20 w = weak, m = medium, and s = strong and a pharmaceutically acceptable carrier, diluent or solvent.

25 18. A medicine for treating diabetic ailments, the medicine comprising a polymorphic form 6 of Troglitazone having the formula I,



characterized by the data:


DSC: Endotherm at 105.4°C. (onset at 94.8°C.);

X-ray powder diffraction (2θ): 5.36, 8.54, 10.24, 10.70, 11.24, 12.48, 12.68, 15.58, 18.84, 19.48, 19.74, 20.58, 21.38, 21.56, 22.18; and

Infrared absorption bands (cm⁻¹): 3634(w), 3514(w), 3176(w), 3060(w), 2930(w), 1753(m), 1686(s), 1610(w), 1512(s), 1459(w), 1418(w), 1380(w), 1335(m), 1300(m), 1253(s), 1164(s), 1106(w), 1087(w), 1058(w), 1048(w), 937(w), 828(m), 723(w), 673(w), 606(w), 568(w), 515(w) wherein

w = weak, m = medium, and s = strong and a pharmaceutically acceptable carrier, diluent or solvent.

19. Use of a polymorphic form 1 of Troglitazone having the form I,



characterized by the data:

DSC: Endotherm at 179.3°C. (onset at 169.3°C.);


X-ray powder diffraction (2θ): 5.56, 11.10, 11.66, 15.72, 16.62, 17.62, 18.24, 19.70, 21.20, 21.42, 23.40, 23.70; and

- 42 -

Infrared absorption bands (cm^{-1}): 3442(w), 3218(w), 2921(w), 1748(m), 1686(s), 1610(w), 1582(w), 1513(s), 1454(w), 1420(w), 1382(w), 1302(m), 1244(s), 1169(m), 1118(w), 1086(w), 1048(m), 931(w), 863(w),
5 827(w), 798(w), 720(w), 509(w) wherein

w = weak, m = medium, and s = strong for the treatment of diabetic ailments.

20. Use of a polymorphic form 2 of Troglitazone having the formula I,



10 characterized by the data:

DSC: Endotherms at 110.1°C. (onset at 102.4°C.) and at 175.1°C. (onset at 155.9°C.);

X-ray powder diffraction (2 θ): 5.42, 10.24, 10.72, 11.58, 11.72, 15.60, 17.56, 18.16, 19.48, 19.58,
15 19.68, 21.44, 22.20, 23.28, 23.66, 24.14, 24.38; and

Infrared absorption bands (cm^{-1}): 3506(w), 3187(w), 3061(w), 2931(w), 1751(m), 1688(s), 1610(w), 1583(w), 1512(s), 1454(w), 1419(w), 1381(w), 1334(w), 1301(m), 1252(s), 1165(m), 1088(w), 1047(w), 932(w),
20 828(w), 722(w), 511(w) wherein

w = weak, m = medium, and s = strong for the treatment of diabetic ailments.

21. Use of a polymorphic form 3 of Troglitazone having the formula I,

- 43 -

characterized by the data:


DSC: Endotherm at 185.8°C. (onset at 175.4°C.);

X-ray powder diffraction (2θ): 5.44, 11.74, 13.24, 15.62, 16.02, 17.56, 18.12, 19.65, 21.41, 23.00, 23.31, 23.65, 24.43, 26.51; and

Infrared absorption bands (cm⁻¹): 3439(w), 3295(w), 2972(w), 2932(w), 1747(m), 1690(s), 1611(w), 1582(w), 1512(s), 1453(m), 1384(w), 1302(m), 1245(s), 1221(s), 1169(s), 1143(w), 1119(w), 1089(w), 1049(w), 931(w), 828(w), 722(w), 510(w) wherein

w = weak, m = medium, and s = strong for the treatment of diabetic ailments.

22. Use of a polymorphic form 4 of Troglitazone
15 having the formula I,



characterized by the data:


DSC: Endotherm at 56.6°C., exotherm at 110.4°C. (onset at 93.6°C.) and endotherm 177.1°C. (onset at 153.7°C.);

20 X-ray powder diffraction (2θ): No diffraction peaks due to its amorphous nature; and

Infrared absorption bands (cm⁻¹): 3473(w), 3204(w), 3060(w), 2924(w), 1754(m), 1696(s), 1610(w), 1583(w), 1512(s), 1457(m), 1420(w), 1378(w), 1333(m), 1301(m), 1243(s), 1162(m), 1115(w), 1085(w), 1041(w), 928(w), 849(w), 827(w), 715(w), 664(w), 512(w) wherein

w = weak, m = medium, and s = strong for the treatment of diabetic ailments.

23. Use of a polymorphic form 5 of Troglitazone
30 having the formula I,




characterized by the data:

DSC: Endotherm at 180.5°C. (onset at 157.9°C.);

X-ray powder diffraction (2 θ): 5.60, 11.06,
5 11.62, 15.48, 15.78, 16.48, 18.12, 18.34, 21.06, 21.90,
23.34, 23.58; and

Infrared absorption bands (cm⁻¹): 3462(w),
3211(w), 3060(w), 2921(w), 1756(m), 1685(s), 1610(w),
1583(w), 1513(s), 1454(m), 1419(w), 1381(w), 1303(m),
10 1244(s), 1168(m), 1117(w), 1085(w), 1047(m), 929(w),
861(w), 825(w), 718(w), 665(w), 564(w), 509(w) wherein
w = weak, m = medium, and s = strong for the
treatment of diabetic ailments.

24. Use of a polymorphic form 6 of Troglitazone
15 having the formula I,



characterized by the data:

DSC: Endotherm at 105.4°C. (onset at 94.8°C.);

X-ray powder diffraction (2 θ): 5.36, 8.54,
20 10.24, 10.70, 11.24, 12.48, 12.68, 15.58, 18.84, 19.48,
19.74, 20.58, 21.38, 21.56, 22.18; and


Infrared absorption bands (cm⁻¹): 3634(w),
3514(w), 3176(w), 3060(w), 2930(w), 1753(m), 1686(s),

- 45 -

1610(w), 1512(s), 1459(w), 1418(w), 1380(w), 1335(m), 1300(m), 1253(s), 1164(s), 1106(w), 1087(w), 1058(w), 1048(w), 937(w), 828(m), 723(w), 673(w), 673(w), 606(w), 568(w), 515(w) wherein

5 w = weak, m = medium, and s = strong for the treatment of diabetic ailments.

25. Use of a polymorphic form 1 of Troglitazone having the formula I,



characterized by the data:


10 DSC: Endotherm at 179°C. (onset at 169.3°C.);

X-ray powder diffraction (2θ): 5.56, 11.10, 11.66, 15.72, 16.62, 17.62, 18.24, 19.70, 21.20, 21.42, 23.40, 23.70; and

15 Infrared absorption bands (cm⁻¹): 3442(w), 3218(w), 2921(w), 1748(m), 1686(s), 1610(w), 1582(w), 1513(s), 1454(w), 1420(w), 1382(w), 1302(m), 1244(s), 1169(m), 1118(w), 1086(w), 1048(m), 931(w), 863(w), 827(w), 798(w), 720(w), 509(w) wherein

20 w = weak, m = medium, and s = strong for the manufacture of a medicament for the treatment of diabetic ailments.

26. Use of a polymorphic form 2 of Troglitazone having the formula I,



- 46 -

characterized by the data:


DSC: Endotherms at 110.1°C. (onset at 102.4°C.) and at 175.1°C. (onset at 155.9°C.);

X-ray powder diffraction (2θ): 5.42, 10.24,
5 10.72, 11.58, 11.72, 15.60, 17.56, 18.16, 19.48, 19.58,
19.68, 21.44, 22.20, 23.28, 23.66, 24.14, 24.38; and

Infrared absorption bands (cm⁻¹): 3506(w),
3187(w), 3061(w), 2931(w), 1751(m), 1688(s), 1610(w),
1583(w), 1512(s), 1454(w), 1419(w), 1381(w), 1334(w),
10 1301(m), 1252(s), 1165(m), 1088(w), 1047(w), 932(w),
828(w), 722(w), 511(w) wherein

w = weak, m = medium, and s = strong for the
manufacture of a medicament for the treatment of
diabetic ailments.

15 27. Use of a polymorphic form 3 of Troglitazone
having the formula I,



characterized by the data:


DSC: Endotherm at 185.8°C. (onset at 175.4°C.);

20 X-ray powder diffraction (2θ): 5.44, 11.74,
13.24, 15.62, 16.02, 17.56, 18.12, 19.65, 21.41, 23.00,
23.31, 23.65, 24.43, 26.51; and

Infrared absorption bands (cm⁻¹): 3439(w),
3295(w), 2972(w), 2932(w), 1747(m), 1690(s), 1611(w),
25 1582(w), 1512(s), 1453(m), 1384(w), 1302(m), 1245(s),
1221(s), 1169(s), 1143(w), 1119(w), 1089(w), 1049(w),
931(w), 828(w), 722(w), 510(w) wherein

w = weak, m = medium, and s = strong for the
manufacture of a medicament for the treatment of
30 diabetic ailments.

28. Use of a polymorphic form 4 of Troglitazone having the formula I,



characterized by the data:


DSC: Endotherm at 56.6°C., exotherm at 110.4°C. (onset at 93.6°C.) and endotherm 177.1°C. (onset at 153.7°C.);

X-ray powder diffraction (2θ): No diffraction peaks due to its amorphous nature; and

Infrared absorption bands (cm⁻¹): 3473(w), 3204(w), 3060(w), 2924(w), 1754(m), 1696(s), 1610(w), 1583(w), 1512(s), 1457(m), 1420(w), 1378(w), 1333(m), 1301(m), 1243(s), 1162(m), 1115(w), 1085(w), 1041(w), 928(w), 849(w), 827(w), 715(w), 664(w), 512(w) wherein

w = weak, m = medium, and s = strong for the manufacture of a medicament for the treatment of diabetic ailments.

29. Use of a polymorphic form 5 of Troglitazone having the formula I,



characterized by the data:

DSC: Endotherm at 180.5°C. (onset at 157.9°C.);

X-ray powder diffraction (2θ): 5.60, 11.06, 11.62, 15.48, 15.78, 16.48, 18.12, 18.34, 21.06, 21.90,


- 48 -

23.34, 23.58; and

Infrared absorption bands (cm^{-1}): 3462(w), 3211(w), 3060(w), 2921(w), 1756(m), 1685(s), 1610(w), 1583(w), 1513(s), 1454(m), 1419(w), 1381(w), 1303(m), 1244(s), 1168(m), 1117(w), 1085(w), 1047(m), 929(w), 861(w), 825(w), 718(w), 665(w), 564(w), 509(w) wherein

w = weak, m = medium, and s = strong for the manufacture of a medicament for the treatment of diabetic ailments.

30. Use of a polymorphic form 6 of Troglitazone having the formula I,



characterized by the data:

DSC: Endotherm at 105.4°C. (onset at 94.8°C.);

X-ray powder diffraction (2 θ): 5.36, 8.54, 10.24, 10.70, 11.24, 12.48, 12.68, 15.58, 18.84, 19.48, 19.74, 20.58, 21.38, 21.56, 22.18; and

Infrared absorption bands (cm^{-1}): 3634(w), 3514(w), 3176(w), 3060(w), 2930(w), 1753(m), 1686(s), 1610(w), 1512(s), 1459(w), 1418(w), 1380(w), 1335(m), 1300(m), 1253(s), 1164(s), 1106(w), 1087(w), 1058(w), 1048(w), 937(w), 828(m), 723(w), 673(w), 606(w), 568(w), 515(w) wherein

w = weak, m = medium, and s = strong for the manufacture of a medicament for the treatment of diabetic ailments.

31. A process for preparing the polymorphic form 1 of Troglitazone of claim 1, which comprises:

(i) synthesizing Troglitazone, in crude form

- 49 -

employing known methods,

(ii) subjecting the crude Troglitazone obtained in step (i) to chromatography to obtain a partially purified Troglitazone having HPLC purity in the range of 60 - 70%.

(iii) dissolving the partially purified Troglitazone obtained in step (ii) in an organic polar solvent, an organic solvent of medium polarity or a mixture thereof and heating the resulting solution with an organic non-polar solvent and

(iv) cooling the resulting solution slowly to room temperature at a rate of 0.1 to 1°C./minute over a period in the range of 24-72 h to produce the polymorphic form 1 of Troglitazone.

32. A process for preparing the polymorphic form 2 of Troglitazone of claim 2, which comprises:

(i) synthesizing Troglitazone, in crude form employing known methods,

(ii) subjecting the crude Troglitazone obtained in step (i) to column chromatography to obtain a partially purified Troglitazone having HPLC purity in the range of 60 - 70%,

(iii) dissolving the partially purified Troglitazone obtained in step (ii) in an organic polar solvent, an organic solvent of medium polarity or a mixture thereof and heating the resulting solution with an organic non-polar solvent and

(iv) scratching the resulting solution, while cooling rapidly to a temperature between 0 to -20°C. at a rate of 2 to 10°C./minute over a period in the range of 10-30 min. to precipitate the polymorphic form 2 of Troglitazone.

33. A process for preparing the polymorphic form 3 of Troglitazone of claim 3, which comprises:

(i) synthesizing Troglitazone, in crude form employing known methods,

(ii) subjecting the crude Troglitazone

- 50 -

obtained in step (i) to column chromatography to obtain a partially purified Troglitazone having HPLC purity in the range of 60 - 70%,

(iii) dissolving the partially purified
5 Troglitazone obtained in step (ii) in an organic polar solvent, an organic solvent of medium polarity or a mixture thereof and heating the resulting solution with an organic non-polar solvent and

(iv) scratching the resulting solution,
10 while cooling rapidly to a temperature between 0 to - 20°C. at a rate of 2 to 10°C./minute over a period in the range of 10-30 min. to precipitate the polymorphic form 2 of Troglitazone,

(v) dissolving the polymorphic form 2 of
15 Troglitazone obtained in step (iv) in an organic polar solvent, an organic solvent of medium polarity or a mixture thereof and heating the resulting solution with an organic non-polar solvent and

(vi) heating the resulting solution and
20 cooling the solution slowly to room temperature at a rate of 0.1 to 1°C./minute over a period in the range of 24-72 h to crystallize polymorphic form 3 of Troglitazone.

34. A process for preparing the polymorphic form
25 4 of Troglitazone of claim 4, which comprises:

(i) synthesizing Troglitazone, in crude form employing known methods,

(ii) subjecting the crude Troglitazone
obtained in step (i) to column chromatography to obtain
30 a partially purified Troglitazone having HPLC purity in the range of 60-70%,

(iii) dissolving the partially purified
Troglitazone obtained in step (ii) in an organic polar solvent, an organic solvent of medium polarity or a
35 mixture thereof and heating the resulting solution with an organic non-polar solvent,

(iv) cooling the resulting solution slowly

- 51 -

to room temperature at a rate of 0.1 to 1°C./minute over a period in the range of 24-72 h to produce the polymorphic form 1 of Troglitazone,

(v) filtering the polymorphic form 1 of
5 Troglitazone and melting it by heating,

(vi) cooling the melt to ambient temperature slowly at a rate of 0.1 to 1°C./minute over a period in the range of 1-4 h to give a glossy transparent material,

10 (vii) grinding the transparent material to a fine powder to yield the polymorphic form 4 of Troglitazone.

35. A process for preparing the polymorphic form 4 of Troglitazone of claim 4, which comprises:

15 (i) synthesizing Troglitazone, in crude form employing known methods,

(ii) subjecting the crude Troglitazone obtained in step (i) to column chromatography to obtain a partially purified Troglitazone having HPLC purity in
20 the range of 60-70%,

(iii) dissolving the partially purified Troglitazone obtained in step (ii) in an organic polar solvent, an organic solvent of medium polarity or a mixture thereof and heating the resulting solution with
25 an organic non-polar solvent,

(iv) scratching the resulting solution while cooling rapidly to a temperature between 0 to -20°C. at a rate of 2 to 10°C./minute over a period in the range of 10-30 min. to precipitate the polymorphic form 2 of
30 Troglitazone,

(v) filtering the polymorphic form 2 of Troglitazone and melting it by heating,

(vi) cooling the melt of step (v) to ambient temperature slowly at a rate of 0.1 to 1°C./minute over
35 a period in the range of 1-4 h to give a glossy transparent material,

(vii) grinding the transparent material to a

- 52 -

fine powder to yield the polymorphic form 4 of Troglitazone.

36. A process for preparing the polymorphic form 4 of Troglitazone of claim 4, which comprises:

5 (i) synthesizing Troglitazone, in crude form employing known methods,

(ii) subjecting the crude Troglitazone obtained in step (i) to column chromatography to obtain a partially purified Troglitazone having HPLC purity in
10 the range of 60-70%,

(iii) dissolving the partially purified Troglitazone obtained in step (ii) in an organic polar solvent, an organic solvent of medium polarity or a mixture thereof and heating the resulting solution with
15 an organic non-polar solvent,

(iv) scratching the resulting solution, while cooling rapidly to a temperature in the range of 0 to -20°C. at a rate of 2 to 10°C./minute over a period in the range of 10-30 min. to precipitate the
20 polymorphic form 2 of Troglitazone,

(v) dissolving the polymorphic form 2 of Troglitazone obtained in step (iv), in an organic polar solvent, an organic solvent of medium polarity or a mixture thereof and heating the resulting solution with
25 an organic non-polar solvent,

(vi) heating the resulting solution and cooling the solution slowly to room temperature at a rate of 0.1 to 1°C./minute, over a period in the range of 24-72 h to crystallize polymorphic form 3 of
30 Troglitazone,

(vii) filtering the polymorphic form 3 of Troglitazone and melting it by heating,

(viii) cooling the melt of step (vii) to ambient temperature slowly at a rate of 0.1 to
35 1°C./minute, over a period in the range of 1-4 h to give a glossy transparent material,

(ix) grinding the transparent material to a

fine powder to yield the polymorphic form 4 of Troglitazone.

37. A process for preparing the polymorphic form 5 Troglitazone of claim 5, which comprises:

- 5 (i) synthesizing Troglitazone, in crude form employing known methods,
- (ii) subjecting the crude Troglitazone obtained in step (i) to column chromatography to obtain a partially purified Troglitazone having HPLC purity in
10 the range of 60-70%,
- (iii) dissolving the partially purified Troglitazone obtained in step (ii) in an organic polar solvent, an organic solvent of medium polarity or a mixture thereof and heating the resulting solution with
15 an organic non-polar solvent,
- (iv) cooling the resulting solution slowly to room temperature at a rate of 0.1 to 1°C./minute, over a period in the range of 24-72 h to produce polymorphic form 1 of Troglitazone,
- 20 (v) filtering the polymorphic form 1 of Troglitazone and melting it by heating,
- (vi) cooling the melt of step (v) to ambient temperature at a rate in the range of 0.1 to 1°C./minute over a period of 1-4 h to give a glossy transparent
25 material,
- (vii) grinding the transparent material to a fine powder to yield polymorphic form 4 of Troglitazone,
- (viii) subjecting the polymorphic form 4 of
30 Troglitazone as obtained in step (vii) to isothermal heating in the range of 60 to 170°C. for a period in the range of 5 min. to 4 h, cooling to ambient temperature slowly at a rate of 0.1 to 1°C./minute, over a period in the range of 1-4 h, followed by
35 grinding to a fine powder to yield the polymorphic form 5 of Troglitazone.

38. A process for preparing polymorphic form 5 of

- 54 -

Troglitazone of claim 5, which comprises:

(i) synthesizing Troglitazone, in crude form employing known methods,

5 (ii) subjecting the crude Troglitazone obtained in step (i) to column chromatography to obtain a partially purified Troglitazone having HPLC purity in the range of 60 - 70%,

10 (iii) dissolving the partially purified Troglitazone obtained in step (ii) in an organic polar solvent, an organic solvent of medium polarity or a mixture thereof and heating the resulting solution with an organic non-polar solvent,

15 (iv) scratching while cooling the rapidly to a temperature in the range of 0 to -20°C. at a rate of 2 to 10°C./minute, over a period in the range of 10-30 min. to precipitate the polymorphic form 2 of Troglitazone,

(v) filtering the polymorphic form 2 of Troglitazone and melting it by heating,

20 (vi) cooling the melt of step (v) to ambient temperature at a rate in the range of 0.1 to 1°C./minute over a period of 1-4 h to give a glossy transparent material,

25 (vii) grinding the transparent material to a fine powder to yield the polymorphic form 4 of Troglitazone,

30 (viii) subjecting the polymorphic form 4 of Troglitazone obtained in step (vii) to isothermal heating in the range of 60 to 170°C. for a period in the range of 5 min. to 4 h, cooling to ambient temperature slowly at a rate of 0.1 to 1°C./minute, over a period in the range of 1-4 h, followed by grinding to a fine powder to yield the polymorphic form 5 of Troglitazone.

35 39. A process for preparing polymorphic form 5 of Troglitazone of claim 5, which comprises:

(i) synthesizing Troglitazone, in crude form

employing known methods,

(ii) subjecting the crude Troglitazone obtained in step (i) to column chromatography to obtain a partially purified Troglitazone having HPLC purity in the range of 60-70%,

(iii) dissolving the partially purified Troglitazone obtained in step (ii) in an organic polar solvent, an organic solvent of medium polarity or a mixture thereof and heating the resulting solution with an organic non-polar solvent,

(iv) scratching the solution of step (iii) while cooling the rapidly to a temperature in the range of 0 to -20°C. at a rate of 2 to 10°C./minute, over a period in the range of 10-30 min. to precipitate the polymorphic form 2 of Troglitazone,

(v) dissolving the polymorphic form 2 of Troglitazone obtained in step (iv) in an organic polar solvent, an organic solvent of medium polarity or a mixture thereof and heating the resulting solutions with an organic non-polar solvent,

(vi) heating the resulting solution and cooling the solution slowly to room temperature at a rate of 0.1 to 1°C./minute, over a period in the range of 24-72 h to crystallize polymorphic form 3 of Troglitazone,

(vii) filtering the polymorphic form 3 of Troglitazone and melting it by heating,

(viii) cooling the melt of step (vii) to ambient temperature at a rate of 0.1 to 1°C./minute, over a period in the range of 1-4 h to give a glossy transparent material,

(ix) grinding the transparent material to a fine powder to yield polymorphic form 4 of Troglitazone,

(x) subjecting the polymorphic form 5 of Troglitazone obtained in step (ix) to isothermal heating in the range of 60 to 170°C. for a period in

the range of 5 min. to 4 h, cooling to ambient temperature slowly at a rate of 0.1 to 1°C./minute, over a period in the range of 1-4 h, followed by grinding to a fine powder to yield the polymorphic form 5 of Troglitazone.

40. A process for preparing polymorphic form 6 of Troglitazone of claim 6, which comprises:

(i) synthesizing Troglitazone, in crude form employing known methods,

10 (ii) subjecting the crude Troglitazone obtained in step (i) to column chromatography to obtain a partially purified Troglitazone having HPLC purity in the range of 60-70%,

(iii) dissolving the partially purified Troglitazone obtained in step (ii) in an organic polar solvent, an organic solvent of medium polarity or a mixture thereof and adding an organic non-polar solvent to the resulting solution and

(iv) cooling the resulting solution rapidly to about 5°C. at a rate of 10°C./minute and maintaining the temperature at about 5°C. for a period of 10-16 h to produce the polymorphic form 6 of Troglitazone,

41. A process for preparing polymorphic form 4 of Troglitazone of claim 4, which comprises:

25 (i) melting a polymorphic form 5 of Troglitazone by heating,

(ii) cooling the melt of step (i) to ambient temperature slowly at a rate of 0.1 to 1°C./minute, over a period in the range of 1-4 h to give a glossy transparent material, and

30 (iii) grinding the transparent material to a fine powder to yield the polymorphic form 4 of Troglitazone.

42. A process for preparing polymorphic form 4 of Troglitazone of claim 4, which comprises:

35 (i) melting a polymorphic form 6 of Troglitazone by heating,

- 57 -

(ii) cooling the melt of step (i) to ambient temperature slowly at a rate of 0.1 to 1°C./minute, over a period in the range of 1-4 h to give a glossy transparent material, and

5 (iii) grinding the transparent material to a fine powder to yield the polymorphic form 4 of Troglitazone.

43. A process for preparing polymorphic form 5 to Troglitazone of claim 5, which comprises:

10 (i) melting polymorphic form 6 of Troglitazone by heating,

(ii) cooling the melt of step (i) to ambient temperature slowly at a rate of 0.1 to 1°C./minute, over a period in the range of 1-4 h to give a glossy
15 transparent material,

(iii) grinding the transparent material to a fine powder to yield polymorphic form 4 of Troglitazone,

(iv) subjecting the polymorphic form 4 of
20 Troglitazone obtained in step (iii) to isothermal heating in the range of 60 to 170°C. for a period in the range of 5 min. to 4 h, cooling to ambient temperature slowly in the range of 5 min. to 4 h, cooling to ambient temperature slowly at a rate of 0.1
25 to 1°C./minute, over a period in the range of 1-4 h followed by grinding to a fine powder to yield polymorphic form 5 of Troglitazone.

44. A pharmaceutical composition according to any one of claims 1-6, comprising at least one of a
30 polymorphic form of Troglitazone selected from the group consisting of polymorphic form 1 of Troglitazone, polymorphic form 2 of Troglitazone, polymorphic form 3 of Troglitazone, polymorphic form 4 of Troglitazone, polymorphic form 5 of Troglitazone and polymorphic form
35 6 of Troglitazone and one or more pharmaceutically acceptable carriers, excipients, or diluents.


45. A method of treating diabetic ailments

- 58 -

comprising administering to a patient in need thereof
at least one of a polymorphic form of Troglitazone
selected from the group consisting of polymorphic form
1 of Troglitazone, polymorphic form 2 of Troglitazone,
5 polymorphic form 3 of Troglitazone, polymorphic form 4
of Troglitazone, polymorphic form 5 of Troglitazone,
and polymorphic form 6 of Troglitazone.

1 / 2 6


FIG.1



SUBSTITUTE SHEET (RULE 26)


2 / 2 6

FIG.2




SUBSTITUTE SHEET (RULE 26)

FIG.3



4 / 2 6


FIG.4



SUBSTITUTE SHEET (RULE 26)

5 / 2 6


FIG.5



SUBSTITUTE SHEET (RULE 26)

8 / 26


FIG.6



SUBSTITUTE SHEET (RULE 26)

7 / 2 6


FIG.7



SUBSTITUTE SHEET (RULE 26)

8 / 2 6


FIG.8



SUBSTITUTE SHEET (RULE 26)


9 / 2 6

FIG. 9




10 / 26

FIG.10



1 1 / 2 6


FIG. II



SUBSTITUTE SHEET (RULE 26)


12 / 26

FIG.12




SUBSTITUTE SHEET (RULE 26)

FIG. 13



1 4 / 2 6


FIG.14




INTENSITY [cps]
SUBSTITUTE SHEET (RULE 26)

15 / 26

FIG.15




SUBSTITUTE SHEET (RULE 26)




SUBSTITUTE SHEET (RULE 26)

17 / 28

FIG. 17




SUBSTITUTE SHEET (RULE 26)



SUBSTITUTE SHEET (RULE 26)


19/26

FIG.19




SUBSTITUTE SHEET (RULE 26)

20 / 26




SUBSTITUTE SHEET (RULE 26)



SUBSTITUTE SHEET (RULE 26)

22 / 26


FIG. 22



SUBSTITUTE SHEET (RULE 26)


23 / 26

FIG. 23




SUBSTITUTE SHEET (RULE 26)

24 / 26



SUBSTITUTE SHEET (RULE 26)


25 / 26



SUBSTITUTE SHEET (RULE 26)

26 / 26

FIG. 26



SUBSTITUTE SHEET (RULE 26)

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/US 97/02577

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07D417/12 A61K31/425

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 139 421 A (SANKYO COMPANY LIMITED) 2 May 1985 cited in the application see claims; examples 1,2 ---	1-45
A	CHEMICAL ABSTRACTS, vol. 110, no. 8, 20 February 1989 Columbus, Ohio, US; abstract no. 63723y, page 394; XP002032814 see abstract & JP 62 234 085 A (SANKYO CO., LTD) 14 October 1987 ---	1-45
A	EP 0 297 019 A (CENTRO MARGA PARA LA INVESTIGACION SA) 28 December 1988 see the whole document -----	1

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- * "A" document defining the general state of the art which is not considered to be of particular relevance
- * "E" earlier document but published on or after the international filing date
- * "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- * "O" document referring to an oral disclosure, use, exhibition or other means
- * "P" document published prior to the international filing date but later than the priority date claimed

- * "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- * "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- * "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- * "&" document member of the same patent family

Date of the actual completion of the international search

11 June 1997

Date of mailing of the international search report

27.06.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+ 31-70) 340-3016

Authorized officer

Henry, J

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 97/02577

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0139421 A	02-05-85	JP 1604002 C	22-04-91
		JP 2031079 B	11-07-90
		JP 60051189 A	22-03-85
		AU 570067 B	03-03-88
		AU 3255984 A	07-03-85
		CA 1263395 A	28-11-89
		DE 3470742 A	01-06-88
		IE 58036 B	16-06-93
EP 0297019 A	28-12-88	US 4572912 A	25-02-86
		AU 1767288 A	22-12-88
		CA 1322760 A	05-10-93
		CN 1030077 A	04-01-89
		DE 3865899 A	05-12-91
		JP 1100162 A	18-04-89
		US 5021582 A	04-06-91
		SU 1704631 A	07-01-92